In this episode, Dr Aleksandra Zuraw looks at the complicated maze of digital pathology reimbursement and how to align it with its value. She speaks to Visiopharm's Chief Clinical and Regulatory Officer, Esther Abels, who contributed to establishing a regulatory pathway for digital pathology.
Esther tells us about the importance of supporting the understanding of the health economic impacts and patient improvements.
“We need to start thinking about is to articulate what the services is that we provide and what is it then that it's uniquely provided to the individual patients. And we need to identify what is the data that we need to figure this out and to make sure that not only the fee goes for the technology, component of the code, but also to the physician’s fee. I think what we should be doing is defining key endpoints and outcomes, and that we have to outline these relevant to demonstration of the value, and of the technology.”
Esther Abels, Chief Clinical and Regulatory Officer at Visiopharm
